https://enigmabiomedicalgroup.com/publications/betthauser-tj-koscik-rl-jonaitis-em-et-al-amyloid-and-tau-imaging-biomarkers-explain-cognitive-decline-from-late-middle-age-brain-2020-1431320-335-doi-10-1093-brain-awz378/2020-07-20T09:01:24+00:00https://enigmabiomedicalgroup.com/publications/belov-v-guehl-n-j-duvvuri-s-iredale-p-moon-s-h-dhaynaut-m-chakilam-s-macdonagh-a-c-rice-p-a-yokell-d-l-renger-j-j-el-fakhri-g-normandin-m-d-2024-pet-i/2026-02-26T12:55:09+00:00https://enigmabiomedicalgroup.com/publications/bodick-n-c-offen-w-w-levey-a-i-cutler-n-r-gauthier-s-g-satlin-a-shannon-h-e-tollefson-g-d-rasmussen-k-bymaster-f-p-hurley-d-j-potter-w-z-paul-s-m-19/2026-02-26T12:55:02+00:00https://enigmabiomedicalgroup.com/publications/tong-l-li-w-lo-m-m-c-gao-x-wai-j-m-c-rudd-m-tellers-d-joshi-a-zeng-z-miller-p-salinas-c-riffel-k-haley-h-purcell-m-holahan-m-gantert-l-schubert-j/2026-02-26T12:49:04+00:00https://enigmabiomedicalgroup.com/publications/shekhar-a-potter-w-z-lightfoot-j-lienemann-j-dube-s-mallinckrodt-c-bymaster-f-p-mckinzie-d-l-felder-c-c-2008-selective-muscarinic-receptor-agonist-xanomeline-as-a-no/2026-02-26T12:49:27+00:00https://enigmabiomedicalgroup.com/publications/pascual-b-zanotti-fregonara-p-yu-m-funk-q-arbones-v-wang-y-li-w-cheng-a-anderson-m-hostetler-e-basile-a-masdeu-j-2021-11cmk-6884-pet-tracer-for-m4-muscarinic/2026-02-26T12:49:49+00:00https://enigmabiomedicalgroup.com/publications/masdeu-j-pascual-b-zanotti-fregonara-p-yu-m-funk-q-arbones-v-rockers-e-wang-y-li-w-cheng-a-anderson-m-hostetler-e-basile-a-2020-11cmk-6884-pet-tracer-for-m/2026-02-26T12:50:17+00:00https://enigmabiomedicalgroup.com/publications/marin-t-belov-v-chemli-y-ouyang-j-najmaoui-y-fakhri-g-e-duvvuri-s-iredale-p-guehl-n-j-normandin-m-d-petibon-y-2025-pet-mapping-of-receptor-occupancy-using-joint/2026-02-26T12:50:35+00:00https://enigmabiomedicalgroup.com/publications/li-w-wang-y-lohith-t-g-zeng-z-tong-l-mazzola-r-riffel-k-miller-p-purcell-m-holahan-m-haley-h-gantert-l-hesk-d-ren-s-morrow-j-uslaner-j-struyk-a-wai/2026-02-26T12:50:55+00:00https://enigmabiomedicalgroup.com/publications/gollapelli-k-k-krizan-i-bhoopal-b-damuka-n-moriarty-c-miller-m-sai-k-k-s-gould-r-w-2025-11cmk-6884-pet-imaging-reveals-lower-m4-muscarinic-acetylcholine-receptor-avai/2026-02-26T12:51:16+00:00https://enigmabiomedicalgroup.com/publications/duvvuri-s-iredale-p-pin-s-smith-d-zhang-j-giugliano-a-koole-m-2024-april-evaluation-of-m4-muscarinic-receptor-occupancy-by-emraclidine-using-11cmk-6884-pet-in-healthy-volu/2026-02-26T12:51:32+00:00https://enigmabiomedicalgroup.com/publications/duvvuri-s-iredale-p-belov-v-guehl-n-moon-s-h-dhaynaut-m-2021-evaluation-of-m4-muscarinic-receptor-occupancy-by-cvl-231-using-11cmk-6884-pet-in-non-human-primates/2026-02-26T12:51:58+00:00https://enigmabiomedicalgroup.com/publications/koscik-rl-betthauser-tj-jonaitis-em-et-al-amyloid-duration-is-associated-with-preclinical-cognitive-decline-and-tau-pet-alzheimers-dement-amst-2020121e12007-doi-10-1002-dad2-12007/2020-07-20T09:08:09+00:00https://enigmabiomedicalgroup.com/publications/therriault-j-benedet-al-pascoal-ta-et-al-association-of-apolipoprotein-e-%ce%b54-with-medial-temporal-tau-independent-of-amyloid-%ce%b2-jama-neurol-2020-774470-479-doi-10-1001-jamaneurol-2/2020-07-20T09:08:31+00:00https://enigmabiomedicalgroup.com/publications/koole-m-lohith-tg-valentine-jl-et-al-preclinical-safety-evaluation-and-human-dosimetry-of-18fmk-6240-a-novel-pet-tracer-for-imaging-neurofibrillary-tangles-mol-imaging-biol-2020-221173-18/2020-07-20T09:08:59+00:00https://enigmabiomedicalgroup.com/publications/laffon-e-buj-s-de-clermont-h-marthan-r-fitting-of-late-dynamic-18fmk6240-pet-scans-for-in-vivo-tau-quantification-eur-j-nucl-med-mol-imaging-2020-4717-8-doi-10-1007-s00259-019-04542-x/2020-06-10T18:34:45+00:00https://enigmabiomedicalgroup.com/publications/luchsinger-ja-palta-p-rippon-b-et-al-sex-differences-in-in-vivo-alzheimers-disease-neuropathy-in-late-middle-aged-hispanics-j-alzheimers-dis-2020-7441243-1252-doi-10-3233-jad-1911/2020-07-20T09:09:25+00:00https://enigmabiomedicalgroup.com/publications/lussier-fz-pascoal-ta-chamoun-m-et-al-mild-behavioral-impairment-is-associated-with-%ce%b2-amyloid-but-not-tau-or-neurodegeneration-in-cognitively-intact-elderly-individuals-alzheimers-dement-2/2020-06-10T18:35:22+00:00https://enigmabiomedicalgroup.com/publications/mccluskey-sp-plisson-c-rabiner-ea-howes-o-advances-in-cns-pet-the-state-of-the-art-for-new-imaging-targets-for-pathophysiology-and-drug-development-eur-j-nucl-med-mol-imaging-2020-472451-4/2020-07-20T09:09:48+00:00https://enigmabiomedicalgroup.com/publications/therriault-j-benedet-al-pascoal-ta-et-al-apoe%ce%b54-potentiates-the-relationship-between-amyloid-%ce%b2-and-tau-pathologies-mol-psychiatry-2020-epub-ahead-of-print-doi-10-101038-s41380-020/2020-06-10T18:35:51+00:00https://enigmabiomedicalgroup.com/publications/zou-j-tao-s-johnson-a-et-al-microglial-activation-but-not-tau-pathology-is-independently-associated-with-amyloid-positivity-and-memory-impairment-neurobiol-aging-2020-8511-21-doi-10-1016-j/2020-07-20T09:10:34+00:00https://enigmabiomedicalgroup.com/publications/aguero-c-dhaynaut-m-normandin-md-et-al-autoradiography-validation-of-novel-tau-pet-tracer-f-18-mk-6240-on-human-postmortem-brain-tissue-acta-neuropathol-commun-2019-7137-doi-10-1186-s404/2020-07-20T09:11:02+00:00https://enigmabiomedicalgroup.com/publications/devanand-dp-andrews-h-kreisl-wc-et-al-antiviral-therapy-valacyclovir-treatment-of-alzheimers-disease-valad-trial-protocol-for-a-randomized-double-blind-placebo-controlled-treatmen/2020-07-20T09:11:27+00:00https://enigmabiomedicalgroup.com/publications/murugan-na-chiotis-k-rodriguez-vieitez-e-lemoine-l-agren-h-nordberg-a-cross-interaction-of-tau-pet-tracers-with-monoamine-oxidase-b-evidence-from-in-silico-modelling-and-in-vivo-imaging-eur-j/2020-07-20T09:14:01+00:00https://enigmabiomedicalgroup.com/publications/leuzy-a-chiotis-k-lemoine-l-et-al-tau-pet-imaging-in-neurodegenerative-tauopathies-still-a-challenge-mol-psychiatry-2019-2481112-1134-doi-10-1038-s41380-018-0342-8/2020-07-20T09:14:23+00:00https://enigmabiomedicalgroup.com/publications/lohith-tg-bennacef-i-vandenberghe-r-et-al-brain-imaging-of-alzheimer-dementia-patients-and-elderly-controls-with-18f-mk-6240-a-pet-tracer-targeting-neurofibrillary-tangle-pathology-j-nucl-med-2/2020-07-20T09:14:44+00:00https://enigmabiomedicalgroup.com/publications/betthauser-tj-cody-ka-zammit-md-et-al-in-vivo-characterization-and-quantification-of-neurofibrillary-tau-pet-radioligand-mk-6240-in-humans-from-alzheimers-disease-dementia-to-young-controls-j-n/2020-07-20T09:15:06+00:00https://enigmabiomedicalgroup.com/publications/guehl-nj-wooten-dw-yokell-dl-et-al-evaluation-of-pharmacokinetic-modeling-strategies-for-in-vivo-quantification-of-tau-with-the-radiotracer-18fmk6240-in-human-subjects-eur-j-nucl-med-mol-imagin/2020-07-20T09:15:41+00:00https://enigmabiomedicalgroup.com/publications/hopewell-r-ross-k-kostikov-a-et-al-a-simplified-radiosynthesis-of-18fmk-6240-for-tau-pet-imaging-j-labelled-comp-radiopharm-2019-622109-114-doi-10-1002-jlcr-3695/2020-07-25T03:35:14+00:00https://enigmabiomedicalgroup.com/publications/salinas-c-lohith-tg-purohit-a-et-al-test-retest-characteristic-of-18fmk-6240-quantitative-outcomes-in-cognitively-normal-adults-and-subjects-with-alzheimers-disease-j-cereb-blood-flow/2020-07-20T09:16:35+00:00https://enigmabiomedicalgroup.com/publications/tago-t-toyohara-j-harada-r-et-al-characterization-of-the-binding-of-tau-imaging-ligands-to-melanin-containing-cells-putative-off-target-binding-site-ann-nucl-med-2019-336375-382-doi-10/2020-07-20T09:16:57+00:00https://enigmabiomedicalgroup.com/publications/murugan-na-nordberg-a-agren-h-different-positron-emission-tomography-tau-tracers-bind-to-multiple-binding-sites-on-the-tau-fibril-insight-from-computational-modeling-acs-chem-neurosci-2018-97/2020-07-20T09:17:19+00:00https://enigmabiomedicalgroup.com/publications/okamura-n-harada-r-ishiki-a-et-al-the-development-and-validation-of-tau-pet-tracers-current-status-and-future-directions-clin-transl-imaging-2018-64305-316-doi-10-1007-s40336-018-0290-y/2020-07-20T09:17:41+00:00https://enigmabiomedicalgroup.com/publications/pascoal-ta-shin-m-kang-ms-et-al-in-vivo-quantification-of-neurofibrillary-tangles-with-18fmk-6240-alzheimers-res-ther-2018-1011-14-doi-10-1186-s13195-018-0402-y/2020-06-10T18:38:19+00:00https://enigmabiomedicalgroup.com/publications/collier-tl-yokell-dl-livni-e-et-al-cgmp-production-of-the-radiopharmaceutical-18fmk-6240-for-pet-imaging-of-human-neurofibrillary-tangles-j-labelled-comp-radiopharm-2017-605263-269-doi-1/2020-07-20T09:18:01+00:00https://enigmabiomedicalgroup.com/publications/hostetler-ed-walji-am-zeng-z-et-al-preclinical-characterization-of-18f-mk-6240-a-promising-pet-tracer-for-in-vivo-quantification-of-human-neurofibrillary-tangles-j-nucl-med-2016-57101599-16/2020-07-20T09:18:43+00:00https://enigmabiomedicalgroup.com/publications/walji-am-hostetler-ed-selnick-h-et-al-discovery-of-6-fluoro-18f-3-1h-pyrrolo23-cpyridin-1-ylisoquinolin-5-amine-18f-mk-6240-a-positron-emission-tomography-pet-imaging-agent-for-q/2020-07-20T09:19:14+00:00